After the United States warned that it may cause rare neurological diseases, the European Medicines Agency once again reviewed the safety of vaccines produced by Johnson & Johnson.
In a statement to Reuters on Tuesday, the European Medicines Agency (EMA) said it was looking at data on the safety of Johnson & Johnson’s Covid-19 vaccine.This “The EMA’s Safety Committee (PRAC) is analysing [J&J]… Regarding the reported cases of Guillain-Barré syndrome (GBS) after vaccination,” it says.
The drug administration did not provide any detailed information on whether potential cases of GBS were observed, but added that its review is part of the regular safety summary report.
On Monday, the US Food and Drug Administration (FDA) added a GBS warning to the Johnson & Johnson vaccine fact sheet that the vaccine has been investigated for possible fatal blood clotting.
The FDA stated that 100 preliminary GBS reports are under investigation, including 95 severe cases requiring hospitalization and 1 reported death.
According to data from the European Center for Disease Control and Prevention, the United States has vaccinated 12.6 million people in a single shot and distributed 18.6 million doses of vaccine across the European Union.
Some experts suggest that people who receive a single injection of Johnson & Johnson’s vaccine may need to intensify the injection in the next few months, because the new variant will affect the efficacy of the injection.
If you like this story, share it with your friends!
